The EIF4EBP1 Knockout A2780 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell pool in the A2780 ovarian carcinoma background, featuring targeted gene disruption of EIF4EBP1. This polyclonal population preserves mutagenesis diversity, avoiding clonal artifacts and enabling robust, population-level functional analyses. The heterogeneous knockout pool recapitulates the genetic variability observed in tumor cell populations, making it suitable for studies requiring representative cellular responses.
The A2780 cell line was established from a patient with ovarian carcinoma and serves as a widely used epithelial ovarian cancer model. These cells retain key features of high-grade serous ovarian cancer, including aberrant signaling that drives proliferation and survival. Their extensive characterization provides a reliable platform for investigating tumor biology, drug response, and the molecular mechanisms of oncogenesis, particularly in the context of translational control.
EIF4EBP1 encodes the eIF4E-binding protein 1 (4E-BP1), a critical translational repressor that binds eIF4E to inhibit cap-dependent translation initiation. Hypophosphorylated 4E-BP1 sequesters eIF4E, blocking assembly of the eIF4F complex and repressing synthesis of proteins such as cyclin D1, c-Myc, and VEGF. Upon growth factor or insulin stimulation, mTORC1 (consisting of mTOR, Raptor, and mLST8) phosphorylates 4E-BP1, releasing eIF4E to interact with eIF4G and promote translation. mTORC1 is regulated upstream by the PI3K-AKT and ERK-RSK pathways via the TSC1-TSC2-Rheb axis, with additional input from p90S6K. Consequently, 4E-BP1 integrates mitogenic and survival signals to control the translation of key pro-growth proteins.
In ovarian cancer, mTOR signaling is often hyperactivated, leading to constitutive 4E-BP1 phosphorylation and derepression of oncogenic translation. EIF4EBP1 knockout in A2780 cells enables dissection of 4E-BP1-dependent and -independent effects on proliferation, chemosensitivity, and mTOR inhibitor response. The model allows assessment of how loss of translational repression impacts downstream targets such as cyclin D1 and c-Myc, and helps identify compensatory mechanisms that emerge upon mTOR inhibition. Combined with pharmacological agents, these cells facilitate the study of resistance pathways and therapeutic vulnerabilities in ovarian carcinoma.
These polyclonal knockout cells support diverse experimental workflows, including western blotting for total and phospho-4E-BP1 to confirm gene disruption, and cap-binding or polysome profiling assays to measure translation efficiency. RT-qPCR for ccnd1, myc, and vegfa distinguishes transcriptional from translational regulation. Functional assays encompass proliferation, colony formation, and drug sensitivity screening with mTOR inhibitors like rapamycin, while flow cytometry enables cell cycle and apoptosis analyses. This tool is ideal for investigating mTOR-driven translation control, drug resistance mechanisms, and target validation. For additional information, please contact Ascent Research.
